Five NIH study section members resign over peer review of their grant proposals. Review inequitable for study section members, they say.
FDA orders “limited distribution” for lung cancer drug Iressa.
House approves $210 million for Dept. of Defense cancer research programs.
House Committee on Appropriations approves $28.5 billion for NIH.
House panel investigating NIH handling of tissue specimens.
Trending Stories
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit
Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology - What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State
- Breast cancer activists in the 90s got DOD to fund cancer research—now that program has been gutted
- In The Headlines: HHS shakeup threatens a legacy of medical breakthroughs